|
Name |
(2R)-2-[3-(2,3-Dihydroxy-3-methylbutyl)-4-hydroxybenzyl]-3-(4-hydroxyphenyl)-4-hydroxy-5-oxo-2,5-dihydrofuran-2beta-carboxylic acid methyl ester
|
Molecular Formula | C24H26O9 | |
IUPAC Name* |
methyl (2R)-2-[[3-(2,3-dihydroxy-3-methylbutyl)-4-hydroxyphenyl]methyl]-4-hydroxy-3-(4-hydroxyphenyl)-5-oxofuran-2-carboxylate
|
|
SMILES |
CC(C)(C(CC1=C(C=CC(=C1)C[C@@]2(C(=C(C(=O)O2)O)C3=CC=C(C=C3)O)C(=O)OC)O)O)O
|
|
InChI |
InChI=1S/C24H26O9/c1-23(2,31)18(27)11-15-10-13(4-9-17(15)26)12-24(22(30)32-3)19(20(28)21(29)33-24)14-5-7-16(25)8-6-14/h4-10,18,25-28,31H,11-12H2,1-3H3/t18?,24-/m1/s1
|
|
InChIKey |
JICCDSOXRQWNCM-VCUSLETLSA-N
|
|
Synonyms |
Butyrolactone VI; (2R)-2-[3-(2,3-Dihydroxy-3-methylbutyl)-4-hydroxybenzyl]-3-(4-hydroxyphenyl)-4-hydroxy-5-oxo-2,5-dihydrofuran-2beta-carboxylic acid methyl ester
|
|
CAS | NA | |
PubChem CID | 49800901 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 458.5 | ALogp: | 2.0 |
HBD: | 5 | HBA: | 9 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 154.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 33 | QED Weighted: | 0.393 |
Caco-2 Permeability: | -5.378 | MDCK Permeability: | 0.00001380 |
Pgp-inhibitor: | 0.009 | Pgp-substrate: | 0.141 |
Human Intestinal Absorption (HIA): | 0.302 | 20% Bioavailability (F20%): | 0.85 |
30% Bioavailability (F30%): | 0.971 |
Blood-Brain-Barrier Penetration (BBB): | 0.053 | Plasma Protein Binding (PPB): | 91.52% |
Volume Distribution (VD): | 0.239 | Fu: | 12.70% |
CYP1A2-inhibitor: | 0.028 | CYP1A2-substrate: | 0.255 |
CYP2C19-inhibitor: | 0.409 | CYP2C19-substrate: | 0.185 |
CYP2C9-inhibitor: | 0.716 | CYP2C9-substrate: | 0.921 |
CYP2D6-inhibitor: | 0.116 | CYP2D6-substrate: | 0.364 |
CYP3A4-inhibitor: | 0.681 | CYP3A4-substrate: | 0.399 |
Clearance (CL): | 10.011 | Half-life (T1/2): | 0.686 |
hERG Blockers: | 0.02 | Human Hepatotoxicity (H-HT): | 0.206 |
Drug-inuced Liver Injury (DILI): | 0.598 | AMES Toxicity: | 0.074 |
Rat Oral Acute Toxicity: | 0.568 | Maximum Recommended Daily Dose: | 0.144 |
Skin Sensitization: | 0.046 | Carcinogencity: | 0.05 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.016 |
Respiratory Toxicity: | 0.013 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002705 | 1.000 | D06KYN | 0.328 | ||||
ENC003497 | 0.847 | D0J7RK | 0.325 | ||||
ENC003493 | 0.847 | D04XEG | 0.316 | ||||
ENC002552 | 0.814 | D0Q9ON | 0.305 | ||||
ENC002729 | 0.740 | D04UTT | 0.305 | ||||
ENC002376 | 0.725 | D0U3YB | 0.296 | ||||
ENC003721 | 0.694 | D04KJO | 0.293 | ||||
ENC002571 | 0.643 | D0Q1IT | 0.293 | ||||
ENC003113 | 0.624 | D0D1DI | 0.293 | ||||
ENC002900 | 0.609 | D00LFB | 0.287 |